CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Soft Tissue Sarcoma
Special Reports in Personalized Cancer Care
Online Continuing Education Activities
SELECT A TOPIC
<< View More Conferences
2017 International Liver Congress
Oncology Conference Multimedia
View more videos >>
Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCC
Dr. Bruix Discusses the Success of Regorafenib in HCC
Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC
Oncology Conference Articles
Regorafenib Success Revives Hope in HCC
Jordi Bruix, MD, discusses the success of regorafenib in hepatocellular carcinoma and its impact on the field going forward.
Mipsagargin Demonstrates Clinical Benefit in Patients With Advanced HCC
The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.
SIRT Better-Tolerated Than Sorafenib in Advanced HCC
Liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated in patients with hepatocellular carcinoma, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Potential Biomarker for Survival Emerges in Hepatocellular Carcinoma
alpha fetoprotein level in the blood directly corresponded to the months of posttreatment survival in patients with hepatocellular carcinoma, independent of the type of treatment, regional differences, and disease etiology.
Nivolumab Provides Durable Responses in Sorafenib-Experienced HCC Patients
Sorafenib-experienced patients with advanced hepatocellular carcinoma had long-term responses to nivolumab of more than 1 year, according to findings from the CheckMate-040 trial.
DAA Therapy for Hepatitis C May Increase HCC Recurrence Risk
Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.
Combinations in HCC Gaining Traction
Nadine Abi-Jaoudeh, MD, discusses a study of tirapazamine and transarterial embolization and the promise of combinations in hepatocellular carcinoma.
MicroRNA-34a as a Therapeutic Target in HCC
MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.
Independent Prognostic Markers of HCC Recurrence Identified
Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.
HCC Risk Comparable in Hepatitis C Patients Treated With DAA or Interferon
A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.
The Changing Landscape in Advanced Ovarian Cancer
Exceptional Responder to Pembrolizumab Guides Immunotherapy Progress in Leiomyosarcoma
Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain
Abemaciclib Improves PFS in Phase III MONARCH 3 Breast Cancer Trial
Guideline Emphasizes Emotional, Physical Needs of Myeloma Patients
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2017
Intellisphere, LLC. All Rights Reserved.